Tetrahydrobiopterin in the vascular system

Pteridines

Volumn 12, Issue 3, 2001, Pages 93-120

  Walter, Roland ^a   Schaffner, Andreas ^a   Schoedon, Gabriele ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; 6 PYRUVOYLTETRAHYDROPTERIN SYNTHASE; ARGININE; ASCORBIC ACID; BIOPTERIN; CYTOKINE; DIHYDROFOLATE REDUCTASE; DIHYDROPTERIDINE REDUCTASE; FOLIC ACID DERIVATIVE; FREE RADICAL; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; HEME; HOMOCYSTEINE; HYDROGEN PEROXIDE; HYDROLYASE; MELANIN; MESSENGER RNA; MONOPHENOL MONOOXYGENASE; NEUROTRANSMITTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYGENASE; PHENYLALANINE 4 MONOOXYGENASE; REGULATOR PROTEIN; SEPIAPTERIN REDUCTASE; SUPEROXIDE; TETRAHYDROBIOPTERIN; TRANSCRIPTION FACTOR; UNINDEXED DRUG; VASCULOTROPIN;

ARTICLE; ATHEROSCLEROSIS; AUTOOXIDATION; BIOSYNTHESIS; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENE THERAPY; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; LUNG BLOOD VESSEL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REGENERATION; REPERFUSION INJURY; SAPHENOUS VEIN GRAFT; SIGNAL TRANSDUCTION; SMOKING; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

EID: 0035715781     PISSN: 09334807     EISSN: 21954720     Source Type: Journal    
DOI: 10.1515/pteridines.2001.12.3.93     Document Type: Article

References (288)

1. Note on a yellow pigment in butterflies
2. New tetrahydrobiopterin-dependent systems
3. Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages
4. Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor
5. 2+/calmodulin-dependent nitric oxide synthase from porcine cerebellum, Cofactor-role of tetrahydrobiopterin
6. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells
7. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens
8. Nitric oxide and infection: Another view
9. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
10. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
11. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide
12. Disorders of tetahydrobiopterin and related biogenic amines
13. Tetrahydrobiopterin biosynthesis, regeneration and functions
14. The role of 6R-tetrahydrobiopterin in the nervous system
15. Tetrahydropterin-dependent amino acid hydroxylases
16. Regulation of pteridine-requiring enzymes by the cofactor tetrahydrobiopterin
17. Tetrahydrobiopterin, cytokines, and nitric oxide synthesis
18. Role of tetrahydrobiopterin in the function of nitric oxide synthase, and its cytoprotective effect
19. Tetrahydrobiopterin, nitric oxide and regulation of cerebral arterial tone
20. The pathway from GTP to tetrahydrobiopterin: Three-dimensional structures of GTP cyclohydrolase I and 6-pyruvoyl tetrahydropterin synthase
21. Biosynthesis of nitric oxide: Dependence on pteridine metabolism
22. Biosynthesis and function of tetrahydrobiopterin
23. Biosynthesis and metabolism of tetrahydrobiopterin and molybdopterin
24. The aromatic amino acid hydroxylases
25. Structure and function of the aromatic amino acid hydroxylases
26. Regulation of rat liver phenylalanine hydroxylase. III. Control of catalysis by (6R)-tetrahydrobiopterin and phenylalanine
27. Coordinate regulation of tetrahydrobiopterin turnover and phenylalanine hydroxylase activity in rat liver cells
28. Mammalian nitric oxide synthases
29. Enzymatic function of nitric oxide synthases
30. Heme-mediated oxygen activation in biology: Cytochrome c oxidase and nitric oxide synthase
31. Catalysis by nitric oxide synthase
32. Nitric oxide synthase structure and electron transfer
33. Nitric oxide synthases: Which, where, how, and why?
34. Structure-function aspects in the nitric oxide synthases
35. Direct measurement of nitric oxide generation from nitric oxide synthase
36. Allosteric regulation of neuronal nitric oxide synthase by tetrahydrobiopterin and suppression of auto-damaging superoxide
37. Electron transfer, oxygen binding, and nitric oxide feedback inhibition in endothelial nitric-oxide synthase
38. Role of tetrahydrobiopterin availability in the regulation of nitric-oxide synthase expression in human mesangial cells
39. Modulation of inducible nitric oxide synthase mRNA stability by tetrahydrobiopterin in vascular smooth muscle cells
40. Generation of superoxide by purified brain nitric oxide synthase
41. 2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase
42. Electron spin resonance spin-trapping detection of superoxide generated by neuronal nitric oxide synthase
43. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury
44. Tetrahydrobiopterin-dependent inhibition of superoxide generation from neuronal nitric oxide synthase
45. The ferrous-dioxy complex of neuronal nitric oxide synthase. Divergent effects of L-arginine and tetrahydrobiopterin on its stability
46. Tetrahydrobiopterin-free neuronal nitric oxide synthase: Evidence for two identical highly anticooperative pteridine binding sites
47. Inducible nitric-oxide synthase generates superoxide from the reductase domain
48. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages
49. The cardiovascular effects and implications of peroxynitrite
50. Tetrahydrobiopterin shifts iNOS from a superoxide producing to a peroxynitrite producing enzyme
51. Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors
52. 2+/calmodulin-dependent and tetrahydrobiopterin regulatory process
53. 2 ratio but not ascorbate controls superoxide and nitric oxide generation by eNOS
54. Biology of nitric oxide signaling
55. Glyceryl-ether monooxygenase [EC 1.14.16.5]. A microsomal enzyme of ether lipid metabolism
56. Tetrahydrobiopterin (BH4): Cofactor for dopamine beta hydroxylase (D beta H)
57. A specific tetrahydrobiopterin binding domain on tyrosinase controls melanogenesis
58. A function of tetrahydropteridines as cofactors for indoleamine 2,3-dioxygenase
59. Parallel induction of tetrahydrobiopterin biosynthesis and indoleamine 2,3-dioxygenase activity in human cells and cell lines by interferon-gamma
60. A new pteridine in urine required for the growth of the protozoon Crithidia fasciculata
61. Pterins
62. High-performance liquid chromatographic methods for the quantification of tetrahydrobiopterin biosynthetic enzymes
63. Enhancement of dopamine release in vivo from the rat striatum by dialytic perfusion of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin
64. Production of pteridines during hematopoiesis and T-lymphocyte proliferation: Potential participation in the control of cytokine signal transmission
65. Stimulation of in vitro angiogenesis by tetrahydrobiopterin in bovine aortic endothelial cells
66. Tetrahydrobiopterin as a mediator of PC12 cell proliferation induced by EGF and NGF
67. Tetrahydrobiopterin enhances apoptotic PC12 cell death following withdrawal of trophic support
68. Tetrahydrobiopterin modulates cyclooxygenase-2 expression in human mesangial cells
69. Regulation of melanin biosynthesis in the human epidermis by tetrahydrobiopterin
70. Evidence for specific complex formation between alpha-melanocyte stimulating hormone and 6(R)-L-erythro-5,6,7,8-tetrahydrobiopterin using near infrared Fourier transform Raman spectroscopy
71. alpha-MSH can control the essential cofactor 6-tetrahydrobiopterin in melanogenesis
72. A review of recent advances on the regulation of pigmentation in the human epidermis
73. Epidermal H(2)O(2) accumulation alters tetrahydrobiopterin (6BH4) recycling in vitiligo: Identification of a general mechanism in regulation of all 6BH4-dependent processes?
74. Endothelial cells in physiology and in the pathophysiology of vascular disorders
75. Vascular endothelium: Vasoactive mediators
76. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine
77. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical
78. Nitric oxide as a signaling molecule in the vascular system: An overview
79. Nitric oxide: A physiologic messenger molecule
80. Nitric oxide synthases: Roles, tolls, and controls
81. NO at work
82. Nitric oxide: A physiologic messenger
83. Nitric oxide: Physiology, pathophysiology, and pharmacology
84. Nitric oxide synthase: Role in the genesis of vascular disease
85. Nitric oxide and its role in the cardiovascular system
86. Molecular control of nitric oxide synthases in the cardiovascular system
87. Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions
88. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. Elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity
89. Regulation of 6-pyruvoyltetrahydropterin synthase activity and messenger RNA abundance in human vascular endothelial cells
90. Anoxia/reoxygenation-induced tolerance with respect to polymorphonuclear leukocyte adhesion to cultured endothelial cells. A nuclear factor-kappaB-mediated phenomenon
91. The nitric oxide - Cyclic GMP signal transduction system
92. Pteridine biosynthesis in human endothelial cells. Impact on nitric oxide-mediated formation of cyclic GMP
93. Modulation of human endothelial cell tetrahydrobiopterin synthesis by activating and deactivating cytokines: New perspectives on endothelium-derived relaxing factor
94. Cytokines stimulate GTP cyclohydrolase I gene expression in cultured human umbilical vein endothelial cells
95. Tetrahydrobiopterin-dependent formation of endothelium-derived relaxing factor (nitric oxide) in aortic endothelial cells
96. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin
97. Tetrahydrobiopterin as another EDRF in man
98. Biopterin cofactor biosynthesis: GTP cyclohydrolase, neopterin and biopterin in tissues and body fluids of mammalian species
99. Metabolism of pterins in the cellular immune system of man and mouse
100. Up-regulation of GTP cyclohydrolase I and tetrahydrobiopterin by calcium influx
101. Tetrahydrobiopterin induces vasodilation via enhancement of cGMP level
102. Effect of tetrahydrobiopterin on endothelial function in canine middle cerebral arteries
103. Induction of tetrahydrobiopterin synthesis in human umbilical vein smooth muscle cells by inflammatory stimuli
104. Adenoviral gene transfer of nitric oxide synthase: High level expression in human vascular cells
105. Tetrahydrobiopterin synthesis. An absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle
106. Effects of activating and deactivating cytokines on the functionally linked tetrahydrobiopterin NO pathways in vascular smooth muscle cells
107. Vascular inducible nitric oxide synthase gene therapy: Requirement for guanosine triphosphate cyclohydrolase I
108. Relaxation of vascular smooth muscle and stimulation of cyclic GMP production by tetrahydrobiopterin but not biopterin
109. Exogenous tetrahydrobiopterin causes endothelium-dependent contractions in isolated canine basilar artery
110. Tetrahydrobiopterin, a cofactor for nitric oxide synthase, produces endothelium-dependent dilation of mouse pial arterioles
111. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia
112. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: Evidence for a dysfunctional nitric oxide synthase
113. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus
114. Inhalation of the nitric oxide synthase cofactor tetrahydrobiopterin in healthy volunteers
115. Cytokine-induced venodilatation in humans in vivo: eNOS masquerading as iNOS
116. Tetrahydrobiopterin increases myocardial blood flow in healthy volunteers: A double-blind, placebo controlled study
117. Signal transduction of eNOS activation
118. Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III)
119. Endothelium-derived kinins account for the immediate response of endothelial cells to bacterial lipopolysaccharide
120. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase
121. Molecular cloning and characterization of human endothelial nitric oxide synthase
122. EDRF and nitric oxide production in cultured endothelial cells: Direct inhibition by E. coli endotoxin
123. Differential regulation of constitutive and inducible nitric oxide production by inflammatory stimuli in murine endothelial cells
124. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life
125. Lack of role for nitric oxide (NO) in the selective destabilization of endothelial NO synthase mRNA by tumor necrosis factor-alpha
126. Downregulation of endothelial constitutive nitric oxide synthase expression by lipopolysaccharide
127. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta 1
128. Compartmentalised inducible nitric-oxide synthase activity in septic shock
129. Effects of cytokines on nitric oxide pathways in human vasculature
130. Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages
131. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells
132. Nitric oxide synthase mRNA in endothelial cells: Synergistic induction by interferon-gamma, tumor necrosis factor-alpha and lipopolysaccharide and inhibition by dexamethasone
133. Regulation of inducible nitric oxide synthase gene by interleukin-1 beta in rat vascular endothelial cells
134. Effects of interferon-gamma on nitric oxide synthase activity and endothelin-1 production by vascular endothelial cells
135. GTP cyclohydrolase I mRNA is induced by LPS in vascular smooth muscle: Characterization, sequence and relationship to nitric oxide synthase
136. GTP cyclohydrolase I mRNA induction and tetrahydrobiopterin synthesis in human endothelial cells
137. Tetrahydrobiopterin is a limiting factor of nitric oxide generation in interleukin 1 beta-stimulated rat glomemlar mesangial cells
138. Nitric oxide production depends on preceding tetrahydrobiopterin synthesis by endothelial cells: Selective suppression of induced nitric oxide production by sepiapterin reductase inhibitors
139. Tetrahydrobiopterin-dependent formation of nitrite and nitrate in murine fibroblasts
140. Synergism between interleukin-1 beta and interferon-gamma, an inducer of nitric oxide synthase, in rat lung fibroblasts
141. Tetrahydrobiopterin is required for cytokine-induced nitric oxide production in a murine macrophage cell line (RAW 264)
142. Regulation of inducible nitric oxide production by cytokines in human thyrocytes in culture
143. A cohort of supporting metabolic enzymes is coinduced with nitric oxide synthase in human tumor cell lines
144. Co-induction of nitric oxide and tetrahydrobiopterin synthesis in the myocardium in vivo
145. Regulation of the L-arginine-dependent and tetrahydrobiopterin-dependent biosynthesis of nitric oxide in murine macrophages
146. Inhibition of tetrahydrobiopterin synthesis reduces nitric oxide production by isolated glomeruli in immune complex glomerulonephritis
147. Induction of GTP cyclohydrolase I by bacterial lipopolysaccharide in the rat
148. Lipopolysaccharide treatment in vivo induces tissue expression of GTP cyclohydrolase I mRNA
149. Tetrahydrobiopterin and GTP cyclohydrolase I in a rat model of endotoxic shock: Relation to nitric oxide synthesis
150. Pteridine and nitrite/nitrate formation in experimental septic and traumatic shock
151. Effect of septicaemia on the plasma levels of biopterin and nitric oxide metabolites in rats and rabbits
152. In vivo administration of endotoxin and tumor necrosis factor-alpha produce different effects on constitutive and inducible nitric oxide synthase activity in rat neutrophils and aorta ex vivo
153. N-Acetylserotonin prevents the hypotension induced by bacterial lipopolysaccharides in the rat
154. Inhibition of tetrahydrobiopterin synthesis reduces in vivo nitric oxide production in experimental endotoxic shock
155. Glucocorticoid regulation of nitric oxide and tetrahydrobiopterin in a rat model of endotoxic shock
156. Increased plasma tetrahydrobiopterin in septic shock is a possible therapeutic target
157. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress
158. Adaptive responses of the endothelium to stress
159. Interactions of oxidants with vascular signaling systems
160. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries
161. Inhibition of tetrahydrobiopterin biosynthesis impairs endothelium-dependent relaxations in canine basilar artery
162. Pulsatile stretch stimulates superoxide production in human aortic endothelial cells
163. Endothelial regulation of vasomotion in apoE-deficient mice: Implications for interactions between peroxynitrite and tetrahydrobiopterin
164. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide
165. Acceleration of oxidative stress-induced endothelial cell death by nitric oxide synthase dysfunction accompanied with decrease in tetrahydrobiopterin content
166. Oxidation of tetrahydrobiopterin by peroxynitrite: Implications for vascular endothelial function
167. Tetrahydropterin oxidation without hydroxylation catalyzed by rat liver phenylalanine hydroxylase
168. Peroxidase catalysed aerobic degradation of 5,6,7,8-tetrahydrobiopterin at physiological pH
169. The auto-oxidation of tetrahydrobiopterin
170. Products of the tyrosine-dependent oxidation of tetrahydrobiopterin by rat liver phenylalanine hydroxylase
171. Kinetics and mechanism of tetrahydrobiopterin-induced oxidation of nitric oxide
172. Induction of manganous superoxide dismutase by tumor necrosis factor: Possible protective mechanism
173. Reduced pterins as scavengers for reactive oxygen species
174. Antioxidative activity of 5,6,7,8-tetrahydrobiopterin and its inhibitory effect on paraquat-induced cell toxicity in cultured rat hepatocytes
175. Reduction by tetrahydrobiopterin of H2O2-induced endothelial cell injury
176. Modulation of S-nitroso-N-acetyl-D,L-penicillamine (SNAP) induced HL-60 cell death by tetrahydrobiopterin
177. SIN-1-induced cytotoxicity in cultured endothelial cells involves reactive oxygen species and nitric oxide: Protective effect of sepiapterin
178. Protective effects of tetrahydrobiopterin against nitric oxide-induced endothelial cell death
179. Pteridines as modulators of free radical-induced reactions: An overview
180. Neopterin as an endogenous antioxidant
181. Inhibitory effect of neopterin on NADPH-dependent superoxide-generating oxidase of rat peritoneal macrophages
182. Protective effects of tetrahydroneopterin against free radical-induced injury
183. Inhibitory effect of 5,6,7,8-tetrahydroneopterin on adriamycin-induced cardiotoxicity
184. Suppression of ischemiareperfusion injury in murine models by neopterins
185. Neopterin modulates toxicity mediated by reactive oxygen and chloride species
186. Effect of 5,6,7,8-tetrahydroneopterin on the bovine endothelial cell injury induced by cumene hydroperoxide
187. Effects of pteridines on luminol-dependent chemiluminescence induced by chloramine-T
188. 7,8 Dihydroneopterin inhibits low density lipoprotein oxidation in vitro. Evidence that this macrophage secreted pteridine is an anti-oxidant
189. Spin trapping study of antioxidant properties of neopterin and 7,8-dihydroneopterin
190. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans
191. Potential antiatherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E)
192. Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations
193. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin
194. Effect of vitamin C on the availability of tetrahydrobiopterin in human endothelial cells
195. L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells
196. Serum folate and risk for ischemic stroke. First National Health and Nutrition Examination Survey epidemiologic follow-up study
197. Serum folate and risk of fatal coronary heart disease
198. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans
199. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen
200. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase
201. Homocysteine-induced endothelial superoxide anion production is inhibited by tetrahydrobiopterin and folate
202. Homocysteine and thrombotic disease
203. Atherosclerosis - An inflammatory disease
204. Potential new cardiovascular risk factors: Left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen
205. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: Restoration by folic acid
206. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia
207. Influence of folic acid on postprandial endothelial dysfunction
208. Folic acid reverts dysfunction of endothelial nitric oxide synthase
209. Nitric oxide and the proliferation of vascular smooth muscle cells
210. Interactions between NO and reactive oxygen species: Pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure
211. Atherosclerosis and the two faces of endothelial nitric oxide synthase
212. Cellular and molecular mechanisms of endothelial cell dysfunction
213. Pharmacological concentrations of arginine influence human whole blood viscosity independent of nitric oxide synthase activity in vitro
214. Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox
215. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases
216. Cardiovascular effects of L-arginine
217. Endothelial dysfunction in diabetes mellitus
218. Endothelial dysfunction in diabetes
219. Review of alterations in endothelial nitric oxide production in diabetes: Protective role of arginine on endothelial dysfunction
220. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells
221. Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2-imbalance in insulin-resistant rat aorta
222. Impaired arginine metabolism and NO synthesis in coronary endothelial cells of the spontaneously diabetic BB rat
223. Tetrahydrobiopterin metabolism in the streptozotocin induced diabetic state in rats
224. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin
225. Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats
226. Impaired nitric oxide production in coronary endothelial cells of the spontaneously diabetic BB rat is due to tetrahydrobiopterin deficiency
227. Endothelin antagonism uncovers insulin-mediated vasorelaxation in vitro and in vivo
228. Decreased production of nitric oxide by LPS-treated J774 macrophages in high-glucose medium
229. Cigarette smoking, endothelial injury and cardiovascular disease
230. Smoking impairs the activity of endothelial nitric oxide synthase in saphenous vein
231. Working under pressure: The vascular endothelium in arterial hypertension
232. Endothelial dysfunction in hypertension
233. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats
234. Tetrahydrobiopterin improves impaired endothelium-dependent vasodilation in patients with essential hypertension
235. Endothelial dysfunction in hypercholesterolemia: Mechanisms, pathophysiological importance, and therapeutic interventions
236. Endothelial dysfunction in atherosclerotic mice: Improved relaxation by combined supplementation with L-arginine-tetrahydrobiopterin and enhanced vasoconstriction by endothelin
237. Tetrahydrobiopterin improves endothelium-dependent vasodilation in nitroglycerin-tolerant rats
238. Nitric oxide activity in the atherosclerotic human coronary circulation
239. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis
240. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels
241. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis
242. Explanted vein grafts with an intact endothelium demonstrate reduced focal expression of endothelial nitric oxide synthase specific to atherosclerotic sites
243. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease
244. Intracoronary tetrahydrobiopterin improves endothelial dysfunction in patients with coronary risk factors
245. Tetrahydrobiopterin restores endothelial function in human coronary arteries in vivo
246. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite
247. Expression of inducible nitric oxide synthase in T lymphocytes and macrophages of cholesterol-fed rabbits
248. Expression of extra-cellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: Colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins
249. Inducible nitric oxide synthase colocalizes with signs of lipid oxidation/peroxidation in human atherosclerotic plaques
250. Tetrahydrobiopterin improves endothelial function in human saphenous veins
251. Regulation of inducible nitric oxide synthase (iNOS) and GTP cyclohydrolase I (GTP-CH I) gene expression by ox-LDL in rat vascular smooth muscle cells
252. Endothelial function and dysfunction in heart failure
253. Lack of effect of tetrahydrobiopterin and vitamin C on endothelial function in patients with congestive heart failure
254. Tetrahydrobiopterin improves impaired endothelium-dependent vasodilation in patients with chronic heart failure
255. Anti-hypertensive effects of tetrahydrobiopterin (BH4) on DOCA-salt hypertension in rats
256. The nitric oxide synthase cofactor tetrahydrobiopterin reduces allograft ischemia-reperfusion injury after lung transplantation
257. Effects of tetrahydrobiopterin on endothelial dysfunction in rats with ischemic acute renal failure
258. Involvement of reactive oxygen species and nitric oxide in gastric ischemia-reperfusion injury in rats: Protective effect of tetrahydrobiopterin
259. Restoration of endothelium-dependent vasodilation after reperfusion injury by tetrahydrobiopterin
260. Tetrahydrobiopterin and L-arginine in the ischemia/reperfusion injury
261. Reduction of myocardial infarct size and improvement of myocardial stunning by tetrahydrobiopterin
262. Decreased nitric-oxide synthase activity causes impaired endothelium-dependent relaxation in the postischemic heart
263. Nitric oxide synthase in atherosclerosis and vascular injury: Insights from experimental gene therapy
264. Expression and function of recombinant endothelial NO synthase in coronary artery smooth muscle cells
265. Vascular gene transfer of the human inducible nitric oxide synthase: Characterization of activity and effects on myointimal hyperplasia
266. Optimization of ex vivo inducible nitric oxide synthase gene transfer to vein grafts
267. Effect of adenovirus-mediated nitric oxide synthase gene transfer on vasospasm after experimental subarachnoid hemorrhage
268. Vascular endothelial growth factor (VEGF) and its receptors
269. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells
270. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance
271. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium
272. VEGF induces NO-dependent hyperpermeability in coronary venules
273. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis
274. Activation of Flk-1/KDR mediates angiogenesis but not hypotension
275. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium
276. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium
277. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin
278. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase 1/2 activation in postcapillary endothelium
279. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells
280. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells
281. Cardiovascular gene therapy
282. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia
283. Nitric oxide and experimental lung injury
284. Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension
285. Endothelial dysfunction in the pulmonary vascular bed
286. Nitric oxide and chronic hypoxic pulmonary hypertension: Animal models and human studies
287. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension
288. Methotrexate inhibition of inducible nitric oxide synthase in murine lung epithelial cells in vitro